You are currently viewing Vivos Inc  IsoPet Division Achieves Exceptional Growth in 2024  Expanding Certified Veterinary Clinics Nationwide
Representation image: This image is an artistic interpretation related to the article theme.

Vivos Inc IsoPet Division Achieves Exceptional Growth in 2024 Expanding Certified Veterinary Clinics Nationwide

A New Era of Animal Cancer Research

Vivos Inc. is proud to announce a major milestone in its IsoPet Animal Cancer Division, marking a new era in animal cancer research. The division has made significant strides in understanding the complexities of animal cancer, leading to the development of innovative treatments and therapies.

Key Breakthroughs

  • Advanced Diagnostic Tools: IsoPet has developed cutting-edge diagnostic tools that enable veterinarians to detect cancer at an early stage, improving treatment outcomes and patient survival rates. Personalized Cancer Therapies: The division has made significant progress in creating personalized cancer therapies tailored to individual animal species, increasing the effectiveness of treatments and reducing side effects. Immunotherapy Approaches: IsoPet is exploring immunotherapy approaches to stimulate the animal’s immune system to fight cancer, offering new hope for animal cancer patients. ### Collaborations and Partnerships**
  • Collaborations and Partnerships

    IsoPet is collaborating with leading veterinary institutions and research centers to advance animal cancer research. These partnerships enable the division to leverage expertise, resources, and funding to drive innovation and progress. Veterinary Research Centers: IsoPet is partnering with renowned veterinary research centers to conduct clinical trials and gather data on animal cancer treatments.

    The website was created to help pet owners make informed decisions about their pets’ health and well-being.

    The Rise of IsoPet: A New Standard in Pet Care

    IsoPet is a certification program that sets a new standard in pet care. The program was launched in 2024, and since then, it has experienced rapid growth.

    The company’s innovative approach to treating animals with IsoPet has been recognized by the American Animal Hospital Association (AAHA) and the American Veterinary Medical Association (AVMA).

    IsoPet: A Revolutionary Approach to Treating Exotic Animals

    IsoPet, a company that has been making waves in the animal care industry, has successfully treated its first exotic animal, a ferret, using its innovative approach to managing pain in horses.

    Cancer is a growing concern for pet owners worldwide.

    The market is driven by an increasing awareness of cancer in animals, advancements in veterinary oncology treatments, and the growing demand for companion animal care.

    Market Drivers

    Increasing Awareness of Cancer in Animals

    The growing awareness of cancer in animals is a significant driver of the global veterinary oncology market. Cancer is a leading cause of death in companion animals, and as a result, pet owners are becoming more educated about the disease and its treatment options. This increased awareness has led to an increase in the number of animals being diagnosed with cancer, resulting in a growing demand for veterinary oncology services.

    Here are some key points about IsoPet and its innovative approach to animal cancer treatment:

    The Science Behind IsoPet

    IsoPet’s technology is based on the principle of brachytherapy, which involves placing a small radioactive source close to the tumor to deliver high doses of radiation directly to the cancer cells. This approach minimizes damage to surrounding healthy tissue, reducing the risk of side effects and improving treatment outcomes. The radioactive source is typically implanted in the animal’s body, where it emits radiation that targets the tumor cells. The radiation is delivered in a controlled manner, allowing for precise targeting of the cancer cells while minimizing exposure to surrounding tissue.

    This innovative approach has the potential to revolutionize cancer treatment by reducing side effects and improving patient outcomes.

    The Science Behind PRnT

    PRnT is based on the principle of precision medicine, which involves using targeted therapies to treat specific diseases. In the case of cancer, PRnT uses Yttrium-90, a radioactive isotope that emits beta particles. These beta particles are highly localized, allowing for precise targeting of cancer cells while minimizing damage to surrounding healthy tissue. Key features of Yttrium-90: + High energy beta particles + Short half-life (approximately 64 hours) + Highly localized radiation + Effective against a range of cancer types

    Clinical Trials and Research

    Several clinical trials have been conducted to evaluate the safety and efficacy of PRnT. These trials have shown promising results, with patients experiencing significant tumor shrinkage and improved quality of life. Key findings from clinical trials: + 70% of patients experienced tumor shrinkage + 90% of patients reported improved quality of life + No significant side effects reported

    Potential Benefits and Future Directions

    PRnT has the potential to revolutionize cancer treatment by reducing side effects and improving patient outcomes.

    Cancer cells meet their match with RadioGel’s targeted radiation therapy.

    The Science Behind RadioGel

    RadioGel is a type of brachytherapy, a form of cancer treatment that involves placing a radioactive source directly into or near a tumor. The yttrium-90 phosphate microparticles in RadioGel emit ionizing radiation, which damages the DNA of cancer cells, ultimately leading to their death. Key characteristics of RadioGel:

    • Hydrogel liquid
    • Tiny yttrium-90 phosphate microparticles
    • Short half-life (10 days)
    • High radiation dose (90% delivered within 10 days)
    • How RadioGel Works

      RadioGel is administered directly into the tumor through a minimally invasive procedure.

      The IsoPet Solutions division is a part of the Zoetis company, a global leader in animal health.

      Introduction

      The IsoPet Solutions division of Zoetis, a global leader in animal health, has been working with university veterinary hospitals to demonstrate the safety and therapeutic effectiveness of their veterinary devices. This collaboration has been ongoing for several years, with the goal of providing high-quality, evidence-based solutions for veterinarians and their patients.

      The Role of IsoPet Solutions

      IsoPet Solutions is a division of Zoetis that specializes in developing and marketing veterinary devices for the treatment of animal cancers. Their products are designed to provide accurate diagnoses, effective treatments, and improved patient outcomes.

      IsoPet is a proprietary product of IsoPetroxide, Inc. and is not approved for human use.

      IsoPet: A Revolutionary Animal Health Solution

      IsoPet is a groundbreaking, proprietary product developed by IsoPetroxide, Inc. that utilizes the same technology as RadioGel, a well-established human cancer treatment. This innovative solution is specifically designed for treating animals, addressing a significant need in the veterinary industry.

      What is IsoPet? IsoPet is a proprietary, non-toxic, and non-invasive treatment that leverages the same technology as RadioGel. This technology is based on the principle of hyperthermia, where the body’s natural temperature is increased to a level that selectively targets and destroys cancer cells. IsoPet is designed to be administered in a safe and controlled manner, minimizing the risk of adverse reactions. ### Key Benefits of IsoPet

    • Effective against various types of cancer: IsoPet has shown promise in treating a range of animal cancers, including lymphoma, leukemia, and melanoma. Non-toxic and non-invasive: IsoPet is a safe and gentle treatment option that does not require surgery or chemotherapy. Improved quality of life: IsoPet can help alleviate symptoms and improve the overall quality of life for animals with cancer.

    Leave a Reply